FIGURE 1.

Agents in clinical trials for treatment of Alzheimer's disease on the Index Date of January 1, 2024, as recorded on clinicaltrials.gov. The inner ring shows Phase 3 agents; the middle ring includes Phase 2 agents; the outer ring presents Phase 1 therapies. Agents in green areas are biologics; those in purple areas are disease‐modifying small molecules; agents in orange areas are symptomatic agents addressing cognitive enhancement; and those in the blue sections of the figure target behavioral and neuropsychiatric symptoms. The shape of the icon denotes the population of the trial; the color of the icon denotes the CADRO‐based class of the agent (© J Cummings; M de la Fleur, PhD, Illustrator).